Bausch & Lomb to launch new training programme for independents

Ocular Assistant Programme is designed to help boost practice business

05 May 2015 by Robina Moss

Bausch & Lomb (B+L) will be launching an Ocular Assistant Programme for independent practices at the BCLA clinical conference and exhibition later this month (29–31 May, ACC Liverpool).

The new training modules are designed to provide a specialist service in practices and to boost business growth. All the modules are certified and will enable an added value personal service to be offered to patients, explaining the contact lens fitting and implementation process. 

Alongside the launch of the training modules, B+L will be showcasing its latest contact lens technology on the stand (25), including the new daily multifocal contact lenses from the Biotrue Oneday range. 

The Biotrue lens is made from ‘HyperGel,’ a new material which helps maintain eye health. With over 98% water retention over 16 hours, the Biotrue lens is said “to stay wet, true to its shape, and comfortable, offering clear vision all day.” 

On Sunday, 31 May, B+L will also be hosting live fitting demonstrations of its recently acquired ‘Innovative Sclereals,’ offering insight into the technology behind the lenses which offer a solution for practitioners interested in fitting irregular corneas.

Also that day, B+L professional services consultant, Serena Kalsi, will be discussing digital eye strain and how the increasingly common modern day challenge can be reduced with aspherical contact lenses. The talk will take place in the Pavilion at 11.30am. 

UK general manager for B+L, Gordon Coutts, said: “The BCLA clinical conference and exhibition is one of the largest trade events for practitioners specialising in contact lenses and a great way to connect with the profession. Bausch & Lomb is committed to providing pioneering, innovative solutions for both patients and practices, and we look forward to detailing our latest training programme.”

For more information, visit the B+L website.  

Advertisement

Your comments

You must be logged in to join the discussion. Log in

Comments (0)